Sebelipase Alfa: First Global Approval

[1]  G. Enns,et al.  A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency. , 2015, The New England journal of medicine.

[2]  J. Gargus,et al.  P1212 : Impact of sebelipase alfa on survival and liver function in infants with raidly progressive lysosomal acid lipase deficiency , 2015 .

[3]  J. Gargus,et al.  Effect of sebelipase alfa on survival and liver function in infants with rapidly progressive lysosomal acid lipase deficiency , 2015 .

[4]  C. Sirlin,et al.  Sebelipase alfa over 52 weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency. , 2014, Journal of hepatology.

[5]  Kees Hovingh,et al.  Lysosomal acid lipase deficiency--an under-recognized cause of dyslipidaemia and liver dysfunction. , 2014, Atherosclerosis.

[6]  G. Enns,et al.  Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients With cholesteryl ester storage disease , 2013, Hepatology.

[7]  G. Grabowski.  Therapy for lysosomal acid lipase deficiency: Replacing a missing link , 2013, Hepatology.

[8]  A. Blamire,et al.  Hepatic cholesteryl ester accumulation in lysosomal acid lipase deficiency: Non-invasive identification and treatment monitoring by magnetic resonance , 2013, Journal of hepatology.

[9]  C. Emiliani,et al.  Therapeutic approaches for lysosomal storage diseases: a patent update. , 2013, Recent patents on CNS drug discovery.

[10]  R. Desnick,et al.  Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. , 2013, Journal of hepatology.

[11]  A. Burt,et al.  Recombinant Human Lysosomal Acid Lipase Decreases Hepatic Macrophage Aggregates and Colocalized Fibrosis in a Rat Model of Lysosomal Acid Lipase Deficiency , 2012 .

[12]  A. Burt,et al.  900 RECOMBINANT LYSOSOMAL ACID LIPASE NORMALIZES LIVER WEIGHT, TRANSAMINASES AND HISTOPATHOLOGICAL ABNORMALITIES IN AN MODEL OF CHOLESTERYL ESTER STORAGE DISEASE , 2011 .

[13]  T. Nagy,et al.  SBC-102, a recombinant enzyme replacement therapy corrects clinically relevant phenotypic abnormalities in a rat model of lysosomal acid lipase deficiency , 2011 .

[14]  A. Burt,et al.  Recombinant lysosomal acid lipase normalizes liver weight, transaminases and histopathological abnormalities in an in vivo model of cholesteryl ester storage disease , 2011 .